Cerebrovascular disease is caused by the interaction of both environmental and hereditary factors.Among them,the hereditary factors mainly influerre the occrrence of cerebrovascular disease through gene polymorphisms.This article mainly reviews gene polymorphisms that influence vascular function,including ACEI,Col3A1,Col4AI,KRIT1,PDCD10,Notch3 and ANP.Meanwhile,the literatures were classified and discussed according to the standard of criterion of the evidence grades in medical literatures.Present research situation of the relation between various gene polymorphisms and cerebrovascular diseases is summarized and overviewed.

Objective To evaluate the influence and safety of losartan on high sensitive C-reactive protein(hs-CRP) and serum uric acid(UA) of essential high blood pressure(HBP) patients with hyperuricemia (HUA).Methods Eighty HBP patients complicated with HUA were enrolled and divided into the losartan group with losartan 50 mg/d(n =40) and the nifedipine group with nifedipine gastrointestinal therapeutic system (GITS) 30 mg/d (n =40) for 6 months continuously.The serum levels of hs-CRP,UA,hepatic and renal functions,creatine kinase(CK) and blood pressure were measured.Results Compared with before therapy,the systolic blood pressure(SBP),diastolic blood pressure (DBP) were lower in two groups after 6-month treatment and the differences were statistically significant(losartan group:SBP:(158.5 ± 13.2) mmHg vs.(136.7 ± 9.4) mmHg,t =3.50,P ＜ 0.01 ; DBP:(95.6 ± 8.4) mmHg vs.(83.3 ± 6.4) mmHg,t =3.49,P ＜ 0.01 ; nifedipine group:SBP:(157.7 ± 13.9) mmHg vs.(134.6 ± 8.2) mmHg,t =3.53,P ＜ 0.01 ; DBP:(96.1 ± 8.9) mmHg vs.(81.2±6.8) mmHg,t =3.56,P ＜0.01).The differences in terms of systolic and diastolic blood pressure were not significant at post-treatment between losartan and nifedipine group.The serum levels of hs-CRP and UA were significantly lower after 6-month treatment than before treatment in losartan group ((5.68 ± 1.53) mg/L vs.(3.52 ± 0.57) mg/L,t =3.82,P ＜ 0.01 ; (502 ± 45) μmol/L vs.(450 ± 38) μmol /L,t =3.48,P＜ 0.01),but there was no change in nifedipine group(hs-CRP:(5.61 ± 1.64) mg/L vs.(5.33 ± 1.48) mg/L,t =1.34,P ＞ 0.05 ; UA:(499 ± 43) μmol/L vs.(489 ± 42) μmol/L,t =0.68,P ＞ 0.05).There was no significant change regarding of liver and kidney functions and serum CK in losartan group before and after treatment.No adverse reaction occurred in the losartan group.Conclusion Losartan treatment can decrease serum hs-CRP and UA of HBP patients complicated with HUA,and there is no serious adverse reactions and good security during treatment.

Objective To investigate the risk factors of postpartum haemorrhage(PPH) in placenta previa. Methods A retrospective analysis of 136 cases with placenta previa from Jun.1996 to Dec. 2000 was performed. Results The incidence of placenta previa was 1.24%(136/10967) and the rate of postpartum haemorrhage was 22.06%(30/136). The associated factors of postpartum haemorrhage in placenta previa were history of multiple abortions (more than twice) , previous cesa rean section, elder age, type of placenta previa, no prenatal check, prenatal bleeding and other complications. PPH might happen when the high risk factor score was more than 4. Conclusions The relative factors of postpartum haemorrhage in placenta previa are abortions more than twice, previous cesarean section, older age, types of placenta previa, absence of prenatal check, antepartum hemorrhage and other complications. We can predict PPH by high risk factor score.

ObjectiveTo investigate the clinicopathologic features of lymphoblastic lymphoma (LBL).Methods21 cases of LBL were examined by light microscopy and immunohistochemistry,and analyzed with clinical features.Results21 cases of LBL patients ranging in age from 4 to 86 years old,including 17 cases originated from the lymph nodes, the other 4 were from the nasopharynx, breast, pleura and mediastinum respectively. Histopathologically: lymphoid cells were median sized, showing a diffuse infiltration. The neoplastic cells had fine chromatin, higer nuclei mitoses. The tumors were positive for TdT and CD99.ConculsionPatients especially who have enlarged lymph nodes in adolescents favor the diagnosis of LBL.The tumor cells show a diffuse infiltration,usually with median size,fine chromatin.The positivity for TdT in immunostaining can confirm the diagnosis of LBL.

Objective To investigate the clinical efficacy of combined use of acupuncture and medicine in treating spasmodic torticollis.Method Thirty patients were randomly allocated to a treatment group of 15 cases and a control group of 15 cases. The treatment group received combined use of acupuncture and medicine, and the control group, acupuncture alone.Result Clinical observation lasted one year. There was a statistically significant pre-/post-treatment difference in the Tsui score in the two groups at 6 and 12 months after treatment (P<0.01). There was a statistically significant difference in the Tsui score between at 6 and 12 months after treatment in the two groups (P<0.01); the Tsui score decreased gradually after treatment. There was a statistically significant post-treatment difference in the Tsui score between the two groups at 12 months after treatment (P<0.05); the Tsui score decreased more in the treatment group.Conclusion The cure and marked efficacy rate of combined use of acupuncture and medicine for spasmodic torticollis is higher than that of acupuncture alone. A longer course is needed for acupuncture treatment of spasmodic torticollis and the patient should persevere with the treatment.

AIM To develop a simple reasonable and provable model of hypophysis shut off in rats with dexamethasone. METHODS Dexamethasone 6 mg?kg -1 was injected subcutaneously into two groups of rats at 3:00～3:30 pm on the preceding day. This dose was repeated at 9:00～9:30 am next day. The control group was treated with saline in the same way. One hour later, one of the dexamethasone treated groups was ig with Z47 200 mg?kg -1 , the other dexamethasone treated group and the control group was ig with 0 5% CMC. Then all the groups were ip with 0 086 mol?L -1 HAc in order to generate stress reaction. The reduction of the content of Vit C in adrenal gland was taken as the index of secretion of ACTH. RESULTS The content of Vit C in NS CMC HAc was obviously lower than in Dex CMC HAc group. There were statistically significant differences ( P

The Notch pathway is an evolutionarily conserved signal transduction pathway. It consists of a complex system of interaction. Its function is associated with the embryonic development and cell differentiation regulation. Studies in recent years have demonstrated that Notch pathway is associated with specific human diseases, in which Notch3 signaling pathway is closely associated with the nervous system development and the structural integrity of blood vessels. Notch3 mutation may cause cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.

Objective To investigate the clinical significance of direct antiglobulin test(DAT) in patients with chronic hepatitis B.Methods Column agglutination technique(CAT) and conventional tube technique(CTT) were used to detect red blood cell(RBC) antibodies in a total of 162 samples,including 50 cases of asymptomatic carriers,42 cases of active phases of chronic hepatitis B(CHB) patients,52 cases of severe hepatitis and 18 healthy individuals.Results The RBC count and hemoglobin(Hb) in patients with severe hepatitis were significantly lower than those in asymptomatic carriers,CHB patients and healthy individuals(P

Objective To observe the impact of rosuvastatin on serum Ang-2 and hs-CRP in patients with metabolic syndrome(MS) to collect data on safety of rosuvastatin in treating MS.Methods Eighty MS patients were enrolled and divided into the treatment group(n =40) and the control group(n =40).The treatment group received both antihypertensive therapy and rosuvastatin with a dose of 10 mg/d.While the control group were only given antihypertensive therapy and but not any lipid-lowering drugs.The levels of plasma Ang-2 and hs-CRP and liver and kidney functions were measured and compared before and after 8-week treatment.Results (1) The levels of plasma Ang-2 and hs-CRP were significantly lower after 8 weeks than before treatment in the treatment groups[Ang-2:(0.30±0.01) μg/L vs.(1.81±0.47) μg/L,t =9.02,P ＜0.01 ;hs-CRP:(2.02±0.26) mg/L vs.(6.32±1.28) mg/L,t =5.75,P ＜ 0.01].Whereas statistical difference was not found in the control group[Ang-2:(1.80±0.45) μg/L vs.(1.79±0.48) μg/L,t =0.19,P > 0.05 ; hs-CRP:(6.28±1.34) mg/L vs.(6.20±1.42) mg/L,t =0.23,P ＞ 0.05].(2) After 8 weeks'treatment,the levels of plasma Ang-2 and hs-CRP were significantly lower in the treatment group than in the control group[Ang-2:(0.30±0.01) μg/L vs.(1.79±0.48) μμg/L,t =2.34,P ＜ 0.05 ;(2.02±0.26) mg/Lvs.(6.20±1.42) mg/L,t =2.58,P ＜ 0.05].(3) The adverse reaction in the treatment group was fewer than the control group and the security of rosuvastatin treatment on MS was fine.Conclusion Rosuvastatin can reduce plasma Ang-2 and hs-CRP levels and improve insulin resistance in patients with MS.Its security is fine.

Objective To investigate the efficacy of rosuvastatin on treating patients with metabolic syndrome(MS).Methods Eighty MS patients were divided into rosuvastatin group (n =40) and atorvastatin group(n =40).Patients in rosuvastatin group were received schufftan at dose of 10 mg/d and in atorvastatin group were received lipitor at dose of 10 mg/d orally.Patients were followed-up for 12 weeks.The ratio of apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) and inflammatory factors including high-sensitivity Czreactive protein (hs-CRP),tumor necrosis factor-oα (TNF-α),interleukin-6 (IL-6),and interleukin-18 (IL-18) were measured.Meanwhile Secondary factors:blood lipids,blood glucose,fasting insulin (FIN),insulin resistance index (HOMA-IR),blood pressure,urine albumin excretion rate (UAER),body mass index (BMI).As well as safety indicators:hepatic and renal function and creatine kinase (CK) were detected.Results (1) After 12-week's treatment,the serum levels of ApoB/ApoA1,hs-CRP,TNF-α,IL-6,IL-18,ApoB,total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C),triglyceride (TG),FIN,HOMA-IR,systolic blood pressure (SBP),diastolic blood pressure (DBP),and UAER significantly decreased compared to before treatment in the two groups(rosuvastatin group:1.26 ± 0.25 vs.0.63 ± 0.22,t =4.44 ; (6.89 ± 1.43) mg/L vs.(2.41 ± 0.36) mg/L,t =7.12;(27.63 ±7.12) ng/L vs.(12.98 ±3.74) ng/L,t =4.23;(26.47 ±6.59) ng/L vs.(13.16± 3.55) ng/L,t =4.45;(318.36 ±90.45) ng/L vs.(172.77 ±50.65) ng/L,t =3.92;(1.58 ±0.29) g/L vs.(0.83 ± 0.23) g/L,t =4.20; (5.78 ± 0.86) mmol/L vs.(3.53 ± 0.69) mmol/L,t =3.85 ; (3.52 ± 0.54) mmol/L vs.(2.04±0.49) mmol/L,t =3.89;(2.87 ±0.65) mmol/L vs.(1.91 ±0.57) mmol/L,t =3.78; (12.08 ± 2.87) mU/L vs.(6.87 ± 1.89) mU/L,t =3.98 ; 3.42 ± 0.57 vs.1.60 ± 0.31,t =4.65 ; (144.6 ± 13.3) mm Hg vs.(135.1 ±12.7) mm Hg,t =3.57;(93.6 ±9.5) mm Hg vs.(85.2 ±7.6) mm Hg,t =3.59; (29.86 ± 3.37) μg/min vs.(22.52 ± 2.56) μg/min,t =3.71 ; atorvastatin group:1.24 ± 0.23 vs.0.92 ± 0.24,t =3.74 ; (6.84 ± 1.37) mg/L vs.(3.50 ± 0.75) mg/L,t =4.24 ; (27.22 ± 7.36) ng/L vs.(18.70 ± 5.82) ng/L,t =3.76; (26.28 ±6.84) ng/L vs.(19.34 ± 5.96) ng/L,t =3.75 ; (311.22 ±91.98) ng/L vs.(246.50±74.73) ng/L,t=3.63;(1.56±0.27) g/L vs.(1.14±0.26) g/L,t =3.74;(5.65 ±0.76) mmol/L vs.(4.67±0.65) mmol/L,t =3.68;(3.51 ±0.55) mmol/L vs.(2.65 ±0.57) mmol/L,t =3.70; (2.86±0.68) mmol/Lvs.(2.05 ±0.54) mmol/L,t=3.78;(12.04±2.95) mU/L vs.(8.91 ±2.32) mU/L,t =3.74;3.38 ±0.54 vs.2.18 ±0.35,t =3.80;(144.0 ± 13.8) mm Hg vs.(135.7 ±12.5) mm Hg,t =3.56 ; (93.4 ± 9.3) mm Hg vs.(85.8 ± 8.9) mm Hg,t =3.58 ; (29.77 ± 3.28) μg/min vs.(23.02 ± 2.83) μg/min,t =3.67 ;P ＜ 0.01).ApoA1 and high-density lipoprotein cholesterol (HDL-C) had increase,but there was no significant difference(P ＞ 0.05).Fasting plasma glucose(FPG),2 h postprandial blood glucose (2 hPG) and BMI tended to decrease,but there were no significant differences(P ＞ 0.05).(2)The serum levels of ApoB/ApoA1,hs-CRP,TNF-α,IL-6,IL-18,ApoB,TC,LDL-C,FIN and HOMA-IR in the rosuvastatin group were significantly lower than those in the atorvastatin group at the 12th-week follow-up(t =2.11,2.10,2.09,2.12,2.08,2.07,2.05,2.04,2.04,2.06 respectively; P ＜ 0.05).The serum levels of HDL-C and ApoA1 in the rosuvastatin group tended to increase compared with the atorvastatin group after 12-week treatment (P ＞ 0.05).There were no statistically significant differences in term of TG,SBP,DBP,UAER between the two groups (P ＞ 0.05).(3) The adverse effect in the rosuvastatin group was fewer than that in atorvastatin group.Conclusion Rosuvastatin can reduce ApoB/ApoA1 ratio and the levels of inflammatory cytokines,improve insulin resistance in patients with MS and less adverse effect were seen.